What happened Shares of AC Immune (NASDAQ: ACIU) jumped 15% on Thursday after the Swiss-based biopharmaceutical company released promising data from its early-stage study of ACI-35.030, an experimental vaccine for the treatment of Alzheimer's disease (AD). So what AC Immune's vaccine candidate elicited a "potent" antibody response against pTau -- a protein that scientists believe plays a part in Alzheimer's disease -- in all 32 patients in its Phase 1b/2a clinical trial. "These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population," AC Immune CEO Andrea Pfeifer said in a press release. AC Immune's stock price rose sharply on Thursday. Image source: Getty Images. AC Immune believes the antibodies could help to slow the spread of the pTau protein in the brain. In turn, Pfeifer posits ACI-35.030 could potentially serve as "an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease."Moreover, ACI-35.030 was found to be safe and generally well tolerated, with no adverse events reported. Now what AC Immune said these results support its plans to advance ACI-35.030 into Phase 2/3 clinical trials. The biotech is developing the vaccine candidate in partnership with Janssen Pharmaceuticals, a subsidiary of healthcare giant Johnson & Johnson. 10 stocks we like better than AC Immune SAWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AC Immune SA wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.Source